Systemic Light-Chain Amyloidosis: Evolving Diagnostic Paradigms and Emerging Therapeutic Strategies Beyond ANDROMEDA
- Authors
-
-
Parikshit Nagda
Janardhan rai nagar university
Author
-
Udai bhan Singh Rathore
Author
-
Ghisaram Dewasi
Author
-
- Keywords:
- AL amyloidosis; systemic amyloidosis; daratumumab; ANDROMEDA; plasma cell dyscrasia; light chain; cardiac amyloidosis; amyloid fibril; CAR-T therapy; bispecific antibody; venetoclax; autologous stem cell transplantation; minimal residual disease; proteasome inhibitor; organ response
- Abstract
-
Background: Systemic light-chain (AL) amyloidosis is a clonal plasma-cell disorder whose prognosis hinges on early diagnosis and rapid deepening of haematologic response. The ANDROMEDA trial established daratumumab plus bortezomib, cyclophosphamide, and dexamethasone (CyBorD) as a new standard of first-line care, yet diagnostic delays persist and relapsed/refractory disease remains therapeutically challenging. This systematic review and meta-analysis synthesizes evolving diagnostic paradigms and evaluates emerging therapeutic strategies beyond ANDROMEDA.
Methods: This review was conducted per PRISMA 2020. Randomized trials, cohort studies, and case series (n ≥ 10) reporting on diagnostic modalities or therapies for AL amyloidosis in adults were eligible. Two independent reviewers performed screening, data extraction, and risk-of-bias assessment (RoB 2, ROBINS-I). Random-effects meta-analysis pooled [complete haematologic response (CHR), organ response, overall survival (OS), and grade ≥ 3 adverse events]; heterogeneity was evaluated with I², and certainty appraised with GRADE.
Result and Conclusions: Diagnostic innovation is central to improving outcomes in AL amyloidosis, and post-ANDROMEDA strategies show promising efficacy and acceptable safety. Standardization of response criteria and prospective comparative data are needed. These findings support a biomarker-guided, risk-adapted therapeutic framework.
- Published
- 30-10-2026
- Section
- Review Articles
- License
-
Copyright (c) 2026 Parikshit Nagda, Udai bhan Singh Rathore, Ghisaram Dewasi (Author)

This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
Most read articles by the same author(s)
- Dr Chandrakant Halder, Ghisaram Dewasi, Parikshit Nagda, From Fibroadenomas to Phyllodes: Unraveling the Spectrum and Clinical Profile of Benign Breast Diseases , Current Trends in Medicine and Clinical Research: 2025: Current Trends in Medicine and Clinical Research – Inaugural Editorial Issue
- Abhishek pareek, Preet kanwar, Rishabh Bansal, Bhavya Maheshwari, Anukrati Joshi, Ghisaram Dewasi, Parikshit Nagda, Surgeon-in-the-Loop AI Systems in Robotic Surgery: Enhancing Precision, Efficiency, and Personalization – A Short Narrative Review , Current Trends in Medicine and Clinical Research: 2025: Current Trends in Medicine and Clinical Research – Inaugural Editorial Issue
- Parikshit Nagda, Ghisaram Dewasi, Sakshi Jain, The Case for an ICMR Centre in Southern Rajasthan: A Review with Focus on Udaipur, Salumbar and Pratapgarh , Current Trends in Medicine and Clinical Research: Vol. 5 No. 4 (2026): Volume 5 ( Oct-Dec)
- Parikshit NAGDA, Ghisaram Dewasi, Sakshi Jain, Ritika Godara, Why Southern Rajasthan Needs an ICMR Centre: A Case for Udaipur, Salumbar and Pratapgarh , Current Trends in Medicine and Clinical Research: Vol. 5 No. 4 (2026): Volume 5 ( Oct-Dec)
- Parikshit Nagda, Bridging Molecular Research and Community Healthcare: Emerging Trends in Translational Biomedical Research in India , Current Trends in Medicine and Clinical Research: Vol. 5 No. 4 (2026): Volume 5 ( Oct-Dec)
